Opportunistic Infections (Kaposi sarcoma)

Doxil Recommendation To Treat Cancer in Europe Announced

Published in Cancer Weekly, February 26th, 1996

Sequus Pharmaceuticals, Inc., Menlo Park, California, announced receipt of a unanimous opinion from the European Committee on Proprietary and Medicinal Products (CPMP) recommending marketing authorization, in the 15 member states of the European Union (EU), of the company's long-circulating Stealth liposome formulation of doxorubicin.

The drug is marketed in the United States under the tradename Doxil. The CPMP recommended the use of the drug for both first-line and second-line treatment of AIDS-related Kaposi sarcoma (KS) in patients with low CD4 counts and extensive mucocutaneous or visceral disease. In addition, the CPMP recognized the use of Caelyx as a tradename...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-02-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry